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A B S T R A C T
Background
Buerger’s disease (thromboangiitis obliterans) is a non-atherosclerotic, segmental inflammatory pathology that most commonly affects
the small and medium sized arteries, veins, and nerves in the upper and lower extremities. The etiology is unknown, but involves
hereditary susceptibility, tobacco exposure, immune and coagulation responses. In many cases, there is no possibility of revascularization
to improve the condition. Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or
rest pain.
Objectives
To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological
agent in patients with Buerger’s disease.
Search methods
The Cochrane Vascular Trials Search Co-ordinator searched their Specialised Register (last searched in April 2015) and the Cochrane
Register of Studies (Issue 3, 2015). The review authors searched trial registers and the European grey literature; screened reference lists
of relevant studies, and contacted study authors and major pharmaceutical companies.
Selection criteria
Randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger’s disease.
Data collection and analysis
Two review authors, independently assessed the studies, extracted data and performed data analysis.
Main results
Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin
analogue, and folic acid with placebo. No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline
or compared oral versus intravenous prostanoid.
Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence
interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest pain after 28 days
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(RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence), although amputation rates were similar six
months after treatment (RR 0.32; 95% CI 0.09 to 1.15; 95 participants; one study; moderate quality evidence). When comparing
prostacyclin (iloprost and clinprost) with prostaglandin (alprostadil) analogues, ulcer healing was similar (RR 1.13; 95% CI 0.76 to
1.69; 89 participants; two studies; I² = 0%; very low quality evidence), as was the eradication of rest pain after 28 days (RR 1.57; 95%
CI 0.72 to 3.44; 38 participants; one study; low quality evidence), while amputation rates were not measured. Compared with placebo,
the effects of oral prostacyclin analogue iloprost were similar for: healing ischaemic ulcers (iloprost 200 mcg: RR 1.11; 95% CI 0.54 to
2.29; 133 participants; one study; moderate quality evidence, and iloprost 400 mcg: RR 0.90; 95% CI 0.42 to 1.93; 135 participants;
one study; moderate quality evidence), eradication of rest pain after eight weeks (iloprost 200 mcg: RR 1.14; 95% CI 0.79 to 1.63;
207 participants; one study; moderate quality evidence, and iloprost 400 mcg: RR 1.11; 95% CI 0.77 to 1.59; 201 participants; one
study; moderate quality evidence), and amputation rates after six months (iloprost 200 mcg: RR 0.54; 95% CI 0.19 to 1.56; 209
participants; one study, and iloprost 400 mcg: RR 0.42; 95% CI 0.13 to 1.31; 213 participants; one study). When comparing folic
acid with placebo in patients with Buerger’s disease and hyperhomocysteinaemia, pain scores were similar, there were no new cases of
amputation in either group, and ulcer healing was not assessed (very low quality evidence).
Treatment side effects such as headaches, flushing or nausea were not associated with treatment interruptions or more serious conse-
quences. Outcomes such as amputation-free survival, walking distance or pain-free walking distance, and ankle brachial index were not
assessed by any study.
Overall, the quality of the evidence was very low to moderate, with few studies, small numbers of participants, variation in severity of
disease of participants between studies and missing information regarding for example baseline tobacco exposure.
Authors’ conclusions
Moderate quality evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest
pain and healing ischaemic ulcers in Buerger’s disease, but oral iloprost is not more effective than placebo. Verylow and low quality
evidence suggests there is no difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for
healing ulcers and relieving pain respectively in severe Buerger’s disease. Very-low quality evidence suggests there is no difference in
pain scores and amputation rates between folic acid and placebo, in people with Buerger’s disease and hyperhomocysteinaemia. High
quality trials assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger’s disease are needed.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological treatment for Buerger’s disease
Background
Buerger’s disease is characterized by recurring progressive inflammation and clotting in small and medium arteries and veins of the
hands and feet. Its cause is unknown, but it is most common in men with a history of tobacco use. It is responsible for ulcers and
extreme pain in the limbs of young smokers. In many cases, mainly in patients with the most severe form, there is no possibility of
improving the condition with surgery, and therefore, drugs (pharmacological agents) are used. These can be pharmacological agents,
such as cilostazol, clopidogrel, and pentoxifylline, or medicine derivatives of prostacyclin and prostaglandin, which redirect blood
flow and improve the circulation in affected areas, and theoretically, help to heal ulcers and relieve rest pain. This review assessed the
effectiveness of pharmacological agents in the treatment of patients with Buerger’s disease.
Key results
Our search identified five randomised controlled trials, with a total of 602 participants and a treatment period of around four weeks
(evidence current until April 2015). The comparisons included prostacyclin analogue versus placebo, aspirin, and a prostaglandin
analogue, and folic acid versus placebo. We did not identify studies that assessed pharmacological agents such as cilostazol, clopidogrel
and pentoxifylline, or studies that compared oral prostanoid versus intravenous prostanoid. The included studies assessed derivatives
of prostacyclin and prostaglandin, which have the ability to redirect blood flow and improve the circulation in affected areas.
Moderate quality evidence from one study suggested that intravenous iloprost was effective in healing ulcers and relieving rest pain after
28 days of treatment when compared with oral aspirin, but no differences were found in the rates of amputation. Evidence from two
studies suggested that prostacyclinwas as effective as prostaglandin analogues in healing ulcers (very lowquality evidence) and eradicating
pain at rest (low quality evidence), but rates of amputation were not assessed. Moderate quality evidence from one study suggested
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that there was no difference between placebo and the oral prostacyclin analogue iloprost (200 mcg and 400 mcg) in healing ischaemic
ulcers or eradicating pain at rest after eight weeks and six months, and rates of amputation after six months. Very-low quality evidence
from one study showed no difference between placebo and folic acid, in patients with Buerger’s disease and hyperhomocysteinaemia
(a medical condition characterized by abnormally high level of homocysteine in the blood), in rates of amputation and pain scores.
Ulcer healing was not measured. Treatment side effects, such as headaches or nausea, did not result in treatment interruptions or more
serious consequences. Outcomes such as amputation-free survival, walking distance or pain-free walking distance, and ankle brachial
index were not assessed by any study.
Quality of the evidence
Overall, the quality of the evidence was very low to moderate, with few studies, small numbers of participants, variation in severity of
disease of participants between studies and missing information regarding for example baseline tobacco exposure. High quality trials
assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger’s disease are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral prostacyclin analogue (iloprost) versus placebo for treatment of Buerger’s disease
Patient or population: pat ients with Buerger’s disease
Settings: hospital and community
Intervention: oral prostacyclin analogue (iloprost) in two doses: 200 mcg and 400 mcg
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
placebo oral prostacyclin ana-
logue
Ulcer healing (200
mcg)
Follow-up: 8 weeks
Study population RR 1.11 (0.54 to 2.29) 133
(1 RCT)
⊕⊕⊕©1,2
moderate
171 per 1000 190 per 1000
(93 to 393)
Ulcer healing (400
mcg)
Follow-up: 8 weeks
Study population RR 0.90 (0.42 to 1.93) 135
(1 RCT)
⊕⊕⊕©1,2
moderate
171 per 1000 154 per 1000
(72 to 331)
Ulcer healing (200
mcg)
Follow-up: 6 months
Study population RR 1.19 (0.82 to 1.73) 133
(1 RCT)
⊕⊕⊕©1,2
moderate
414 per 1000 493 per 1000
(340 to 717)
Ulcer healing (400
mcg)
Follow-up: 6 months
Study population RR 1.00 (0.67 to 1.50) 135
(1 RCT)
⊕⊕⊕©1,2
moderate
414 per 1000 414 per 1000
(278 to 621)
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Complete relief of rest
pain (200 mcg)
Follow-up: 8 weeks
Study population RR 1.14 (0.79 to 1.63) 207
(1 RCT)
⊕⊕⊕©1,2
moderate
343 per 1000 391 per 1000
(271 to 559)
Complete relief of rest
pain (400 mcg)
Follow-up: 8 weeks
Study population RR 1.11 (0.77 to 1.59) 210
(1 RCT)
⊕⊕⊕©1,2
moderate
343 per 1000 381 per 1000
(264 to 546)
Complete relief of rest
pain (200 mcg)
Follow-up: 6 months
Study population RR 1.28 (1.00 to 1.64) 207
(1 RCT)
⊕⊕©©1,2,3
low
490 per 1000 627 per 1000
(490 to 804)
Complete relief of rest
pain (400 mcg)
Follow-up: 6 months
Study population RR 1.00 (0.76 to 1.32) 210
(1 RCT)
⊕⊕⊕©1,2
moderate
490 per 1000 490 per 1000
(373 to 647)
Rate of amputation
(200 mcg)
Follow-up: 6 months
Study population RR 0.54 (0.19 to 1.56) 209
(1 RCT)
⊕⊕⊕©1,2
moderate
87 per 1000 47 per 1000
(17 to 136)
Rate of amputation
(400 mcg)
Follow-up: 6 months
Study population RR 0.42 (0.13 to 1.31) 213
(1 RCT)
⊕⊕⊕©1,2
moderate
87 per 1000 37 per 1000
(11 to 114)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
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Very low quality: We are very uncertain about the est imate.
1 one single study (doubt about reproducibility of data), downgraded by one level
2 conf lict of interest not stated but it was not considered suf f icient to downgrade the quality of evidence
3 inconsistent with dose-response ef fect, downgraded by one level
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Buerger’s disease (thromboangiitis obliterans) is a non-atheroscle-
rotic, segmental inflammatory pathology that most commonly af-
fects the small and medium sized arteries, veins and nerves in the
upper and lower extremities (Olin 2000). VonWiniwarter first de-
scribed a patient with the disease in 1879 (von Winiwarter 1879),
but it was Leo Buerger, in 1908, who published a detailed descrip-
tion of the pathological findings on amputated limbs and named
the disease (Buerger 1908).
The prevalence of the disease among all patients with peripheral
arterial disease (PAD) varies from as low as 0.5% to 5.6% inWest-
ern Europe to as high as 45% to 63% in India, and 16% to 66%
in Korea and Japan (Cachovan 1988; Malecki 2009; Olin 2000).
The etiology is unknown, but involves hereditary susceptibility,
tobacco exposure, immune and coagulation responses (Malecki
2009). Currently, a possible infectious etiology is gaining inter-
est, especially after the findings of micro-organisms of the oral
flora in occlusive thrombi in patients with Buerger’s disease and
moderate to severe periodontitis (Iwai 2005; Li 2008). Another
hypothesis is the possible pathogenic role of rickettsial infection
in Buerger’s disease (Bartolo 1987; Fazeli 2013). Features distin-
guishing Buerger’s disease from atherosclerosis include the pathol-
ogy distribution (with involvement of both the upper and lower
extremities), associated superficial venous thrombosis, a paucity
of atherosclerotic risk factors and normal proximal large arteries
(Weinberg 2012).
Diagnosis and complications
The typical patient with Buerger’s disease is a young man (younger
than 40 or 45 years) with a history of tobacco use, who presents
with progressive claudication, ischaemic ulcers, or pain at rest
(Olin 2000); approximately 76% of patients have ischaemic ul-
cerations at the time of presentation (Olin 2006). To date, there
are no unanimous diagnostic criteria for Buerger’s disease. The
most commonly used are Shionoya’s criteria, which comprise: (1)
smoking history; (2) onset of symptoms before the age of 50 years;
(3) infrapopliteal arterial occlusions; (4) either arm involvement
or phlebitis migrans; and (5) absence of atherosclerotic risk fac-
tors other than smoking (Shionoya 1983). All criteria should be
present. The disease is usually confined to the distal circulation and
is almost always infrapopliteal in the legs and distal to the brachial
artery in the arms (Olin 2000). In fact, the distal and diffuse nature
of the disease culminates in critical limb ischaemia (CLI) in ap-
proximately 76%to81%of patients, with poor chances of revascu-
larization (Olin 2006). In patients diagnosed with limb ischaemia,
as in Buerger’s disease, the clinical evaluation is done according to
the Rutherford classification and the Fontaine stages. The Ruther-
ford classification for PAD has seven categories. These are: (0)
asymptomatic; (1) mild claudication; (2) moderate claudication;
(3) severe claudication; (4) rest pain; (5) minor tissue loss, non-
healing ulcer or focal gangrene with diffuse pedal ischaemia; (6)
major tissue loss extending above the transmetatarsal level; and (7)
a functional foot that is no longer salvageable (Rutherford 2005).
The Fontaine classification has four stages: (I) asymptomatic; (II)
intermittent claudication (IC); (III) rest pain; (IV) ulceration or
gangrene, or both (Fontaine 1954). Novo 2004 described a modi-
fied Fontaine classification, the Leriche-Fontaine classification: (I)
asymptomatic or effort pain; (IIA) effort pain or pain-free walking
distance further than 200 metres; (IIB) pain-free walking distance
less than 200 metres; (IIIA) rest pain, ankle arterial pressure higher
than 50 mm Hg; (IIIB) rest pain, ankle arterial pressure lower
than 50 mmHg; (IV) trophic lesions, necrosis or gangrene (Novo
2004). According to Cooper 2004, the risk of any extremity am-
putation during 15.6 years of follow-up in patients with Buerger’s
disease is 25% at five years, 38% at 10 years and 46% at 20 years.
Description of the intervention
In patients with CLI and poor chances of revascularization, as seen
in many patients diagnosed with Buerger’s disease, pharmacolog-
ical treatment is given to improve the blood flow (perfusion) in
the affected extremity. The most commonly used pharmacolog-
ical agents are aspirin, cilostazol (Bedenis 2014; Ruffolo 2010),
prostanoids (Malecki 2009), and bosentan (De Haro 2009).
Aspirin is a drug that inhibits cyclo-oxygenase, which is respon-
sible for the synthesis of thromboxane and prostaglandins. It is
important in cardiac and cerebrovascular atherosclerotic diseases,
as it inhibits platelet aggregation. The most important contraindi-
cations are hypersensitivity to salicylates, active gastrointestinal ul-
cers, patients with hemorrhagic disorders, renal and hepatic fail-
ure, pregnancy and use in children. Aspirin is administered orally
with a recommended dosage of 75 to 325 mg (Brunton 2011).
Cilostazol is a quinolinone derivative drug that inhibits cellular
phosphodiesterase (more specific for phosphodiesterase III), af-
fecting both vascular beds and cardiovascular function. It causes a
non-homogeneous dilation of vascular beds, with greater dilation
in the femoral beds than in vertebral, carotid or superior mesen-
teric arteries. In other words, cilostazol ’steals’ a small part of the
blood from other territories (gastrointestinal and cerebral) to im-
prove perfusion in ischaemic limbs. A further action of cilostazol is
the reversible inhibition of platelet aggregation. Cilostazol is con-
traindicated in patients with congestive heart failure (CHF) of any
severity, haemostatic disorders or active pathologic bleeding, such
as bleeding peptic ulcer and intracranial bleeding, and in patients
with known or suspected hypersensitivity to cilostazol. The more
common side effects of cilostazol use include headaches, diarrhoea,
abnormal stools and palpitations (Chapman 2003). Cilostazol is
administered orally and is available in 50 mg or 100 mg tablets.
Cilostazol was approved by the US Food and Drug Administra-
tion (FDA) in 1999 for the reduction of symptoms of intermit-
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tent claudication as a result of atherosclerosis (Dindyal 2009; FDA
1999).
Prostanoids (prostaglandin and prostacyclin analogues) are
eicosanoid derivatives, commonly used for many conditions in-
cluding pulmonary hypertension, sexual impotence, and glau-
coma. Because of their short half-life, around two to three min-
utes, these synthetic drugs must be administrated by continu-
ous intravenous infusion (Safdar 2011). The development of sta-
ble prostacyclin analogues (such as iloprost) with a longer half-
life has allowed the oral use of these drugs. The most important
contraindications are heart failure (caused by arrhythmias, my-
ocardiopathy, valvulopathy, or coronary insufficiency), intracra-
nial haemorrhage, gastrointestinal ulcers, and trauma. Side effects
include headache, flushing, malaise, gastrointestinal distress and,
with higher doses, hypotension. The maximum iloprost dose that
is administered is around 2 ng/kg/min by continuous infusion
(Grant 1992).
Bosentan is a potent and mixed endothelin-A and endothelin-B
receptor antagonist, causing selective vasodilatory effects (Weber
1996). Some important reported side effects are hepatotoxicity
and fluid retention. Bosentan is administered orally, mainly in pa-
tients with pulmonary arterial hypertension, with a recommended
dosage of 62.5 mg (twice daily) to 125 mg (twice daily).
How the intervention might work
Aspirin (acetylsalicylic acid), a thromboxane production inhibitor,
is well-known as an antiplatelet drug, and is used in heart attack
and stroke prevention (Brunton 2011).
Cilostazol, a selective inhibitor of phosphodiesterase III, is used
mainly in patients with IC, and acts as a direct arterial vasodilatator
and inhibits platelet aggregation (Rutherford 2005).
Prostanoids act by binding to specific receptors in the endothelium
(causing vasodilatation) and platelets (inhibiting platelet aggrega-
tion), which causes a transitory increase in arterial peripheral per-
fusion (Brunton 2011). Arterial vasodilatation in ischaemic areas
increases blood perfusion and, consequently, increases the chances
of ulcer healing and improving rest pain. Inhibiting platelet ag-
gregation prevents the occlusion of small arteries and, therefore,
stabilizes the disease.
Bosentan, a potent and mixed endothelin-A and endothelin-B
receptor antagonist, causes selective vasodilatory effects (Weber
1996). Bosentan has been used with success in patients with dig-
ital ulcers and systemic sclerosis (Launay 2006; Matucci-Cerinic
2011), opening the perspective for use in other conditions such as
Buerger’s disease (De Haro 2009).
Therefore, these pharmacological agents are used to improve per-
fusion in ischaemic limbs due to their vasodilatatory and an-
tiplatelet effects. The effects may vary from agent to agent.
Why it is important to do this review
Buerger’s disease is a debilitating condition which can affect ac-
tive, young people. In many cases, no possibility exists of revas-
cularization to improve the condition. Different combinations of
drugs, doses and administration pathways (oral and intravenously)
have been approved for use. However, to date there is no con-
sensus about the best pharmacological treatment for patients with
Buerger’s disease. A systematic review is opportune and extremely
relevant.
O B J E C T I V E S
To assess the effectiveness of any pharmacological agent (intra-
venous or oral) compared with placebo or any other pharmaco-
logical agent in patients with Buerger’s disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) involving pharmacological
agents used in the treatment of Buerger’s disease.
Types of participants
Patients clinically diagnosed with Buerger’s disease.
Types of interventions
We assessed any pharmacological agents used in treating patients
with Buerger’s disease, including drugs utilized for atherosclerotic
diseases, such as aspirin or cilostazol, resulting in the possible com-
parisons listed below:
(1) (Oral or intravenous) prostanoid (e.g. iloprost) versus placebo
(2) Oral prostanoid versus intravenous prostanoid
(3) (Oral or intravenous) prostanoid (e.g. iloprost) versus aspirin
(4) (Oral or intravenous) prostanoid (e.g. iloprost) versus cilostazol
(5) Aspirin versus placebo
(6) Cilostazol versus placebo
(7) Aspirin versus cilostazol
(8) Any pharmacological agent versus placebo or any other phar-
macological agent
Prostanoids could be either prostaglandin or prostacyclin ana-
logues.
We excluded studies that did not assess pharmacological agents in
the treatment of Buerger’s disease.
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Types of outcome measures
Primary outcomes
(1) Ulcer healing
(2) Pain: assessed using a validated pain score or scale, or quality
of life (QoL) questionnaire
(3) Rate of amputation: major amputation (defined as amputation
of the lower or upper limb above the ankle or the wrist, respec-
tively); and minor amputation (defined as amputation of a hand
or foot or any part of )
Secondary outcomes
(1) Amputation-free survival
(2) Side effects of pharmacological agents, including bleeding,
headache, flushing, or nausea
(3) Walking distance or pain-free walking
(4) Ankle brachial index
Search methods for identification of studies
There were no language restrictions.
Electronic searches
The Cochrane Vascular Trials Search Co-ordinator (TSC)
searched their SpecialisedRegister (last searched inApril 2015) and
theCochrane Register of Studies (CRS) http://www.metaxis.com/
CRSWeb/Index.asp (Issue 3, 2015). See Appendix 1 for details of
the search strategy used to search the CRS. The Specialised Reg-
ister is maintained by the TSC and is constructed from weekly
electronic searches of MEDLINE, EMBASE, CINAHL, AMED,
and through handsearching relevant journals. The full list of the
databases, journals and conference proceedings which have been
searched, as well as the search strategies used, are described in the
Specialised Register section of the Cochrane Vascular module in
The Cochrane Library (www.cochranelibrary.com).
Trial registers
We searched the following trial registers:
• ISRCTN register (www.isrctn.com) on May 10, 2015;
• ClinicalTrials.gov (www.clinicaltrials.gov) on May 10,
2015;
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au) on May 10, 2015;
• The EU Clinical Trials Register (
www.clinicaltrialsregister.eu) on May 10, 2015;
• The World Health Organization International Clinical
Trials Registry Platform (www.who.int/trialsearch) on May 10,
2015;
• LILACS, Latin American and Caribbean Health Sciences
Literature (http://lilacs.bvsalud.org/) on May 10, 2015.
We used the terms ’Buerger’s disease’; ’thromboangiitis obliter-
ans’; ’von Winiwarter disease’; and word variations to perform the
search.
Grey literature
We searched the grey literature produced in Europe by consulting
the OpenGrey Database (www.opengrey.eu). We used the terms
’Buerger’s disease’; ’thromboangiitis obliterans’; ’von Winiwarter
disease’; and word variations to perform the search.
Searching other resources
We searched the reference lists of relevant articles retrieved by the
electronic searches for additional citations.
We contacted study authors to inquire about ongoing or unpub-
lished studies (Dr JN Fiessinger, Dr K Esato, Dr K Ishitobi, Dr
M Verstraete, Dr MA Hoghoughi, and Dr S Ishimaru). Only Dr
MA Hoghoughi replied, denying new studies. We asked phar-
maceutical companies to provide information on both published
and unpublished trials (Actelion Pharmaceuticals, AstraZeneca,
Bayer Schering Pharma AG, Changzhou Highassay Chemical Co
Ltd, LGMPharma,Manus Aktteva Biopharma LLP,Otsuka Phar-
maceutical Co Ltd, Pfizer Inc, Sandoz Inc). However, only As-
traZeneca and Manus Aktteva Biopharma LLP replied to our cor-
respondence, and both denied ongoing or unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (DGC and JCCBS) independently assessed
all studies that were identified by the search strategy for inclusion.
Disagreements were resolved by the third author (CM).
Data extraction and management
For all eligible studies, two review authors (DGC and JCCBS)
extracted data using the Cochrane Vascular’s data extraction table.
Where there were discrepancies, the third author (CM) solved
disagreement. We entered the data into Review Manager 5.3.
Assessment of risk of bias in included studies
Two review authors (DGC and JCCBS) independently assessed
the included studies for risk of bias using Cochrane’s ’Risk of bias’
tool as described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). The information about the risk
of bias of the included studies was presented in the form of a table
and a graph.
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Measures of treatment effect
Dichotomous (categorical) data
Results were presented as summary risk ratios (RR) with 95%
confidence intervals (CIs).
Continuous data
We had planned to use the mean difference (MD) with 95% CI
where there was consistency in the outcome measure, or the stan-
dardised mean difference (SMD) to combine trials that measured
the same outcome but used different methods.
Time-to-event data
We had planned to use hazard ratios (HR) with 95% CIs to mea-
sure the treatment effect for any time-to-event outcomes.
Unit of analysis issues
We considered the individual participant as the unit of randomi-
sation for a single intervention.
Dealing with missing data
We contacted contact authors of included studies about method-
ological queries, but none of the contact authors answered the so-
licitation. Where possible, we had planned to analyse all outcome
measures on an intention-to-treat basis by including data from all
participants.
Assessment of heterogeneity
The heterogeneity among the eligible studies was quantified using
the Chi² test and I² statistic, specifically using the formula I² = (Q
- df/Q) X 100% where Q was the Chi² statistic and df represented
the degree of freedom. The I² statistic values were interpreted as
follows:
• 0% to 25% = low heterogeneity;
• 25% to 75% = moderate heterogeneity;
• more than 75% = substantial heterogeneity (Higgins 2011)
Where substantial heterogeneity was detected, according to the
criteria above, we had planned to perform a further investigation
based on the pre-specified subgroup analysis.
Assessment of reporting biases
Had sufficient eligible trials been available, we had planned to ex-
plore publication bias through the use of funnel plots and to ex-
plore the presence of time-lag bias in both published and unpub-
lished trials. As a result of the small number of included studies
(five RCTs), these analyses were not performed.
Data synthesis
Review Manager (RevMan 5.3) was used to perform data synthe-
sis. After assessing heterogeneity, we had planned to use a ran-
dom-effects model meta-analysis if substantial heterogeneity be-
tween studies was detected. A fixed-effect model meta-analysis was
planned if the studies estimated the same intervention effect and
had low or moderate heterogeneity (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
If sufficient information had been available, we had intended to
perform subgroup analyses according to the following features:
• tobacco exposure (cigarette, cannabis, or any other form of
smoking, either measured in a laboratory or declared) after the
intervention;
• severity of the ischaemia, according to the Fontaine or
Rutherford classification;
• different doses of the pharmacological agents.
Sensitivity analysis
We had intended to perform sensitivity analyses by looking sepa-
rately at sponsored studies and publication bias, and by excluding
studies with low and moderate methodological quality according
to the ’Risk of bias’ judgements. As a result of the small number
of studies included for each comparison and a meta-analysis with
only two studies, sensitivity analyses were not performed.
Summary of Findings
Wepresented themain findings of the review results for the quality
of evidence, themagnitude of effect of the interventions examined,
and the sum of available data on the primary outcomes (see Types
of outcome measures) in ’Summary of findings’ tables, according
to Higgins 2011 and the GRADE Working group (Atkins 2004).
Since we assessed different intervention comparisons, a ’Summary
of findings’ table was developed for each comparison included in
the Results sections. The GRADEprofiler software was used to
assist in the preparation of the ’Summary of findings’ tables.
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies and Characteristics of studies awaiting classification tables.
Results of the search
A flow diagram of the search results is shown in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Five randomised controlled studies were included in this review,
with a combined total of 602 participants (Beigi 2014; Esato 1995;
Fiessinger 1990; Ishitobi 1991; Verstraete 1998).
Beigi 2014 reported on a study of 30 participants with Buerger’s
disease (Fontaine II of ischaemia) and hyperhomocysteinaemia
(a well known and established risk factor for limb ischaemia in
patients with atherosclerosis), who were receiving folic acid or
placebo (single dose); they compared the number of major and
minor amputations and pain in both groups.
In Esato 1995, 46 participants with Buerger’s disease received
a prostacyclin analogue (clinprost) or a prostaglandin analogue
(alprostadil) for four weeks; they compared improvements in is-
chaemic ulcers and rest pain.
Fiessinger 1990 reported on a European multicentre randomised
study that included 152 participants with Buerger’s disease, in
critical limb ischaemia (rest pain, ulcers or gangrene), who were
receiving prostacyclin analogue (iloprost endovenously) or aspirin
orally for 28 days.
Ishitobi 1991 was a trial of 134 participants with critical limb is-
chaemia, which included 55 participants diagnosed with Buerger’s
disease. The pharmacological treatment assessed the efficacy be-
tween a prostaglandin analogue (alprostadil) and a prostacyclin
analogue (iloprost), both of them administered intravenously for
28 days.
Verstraete 1998 described a large multicentre randomised trial
with 319 participants with Buerger’s disease with rest pain, is-
chaemic ulcers, or both, who were administered a prostaglandin
analogue (iloprost) orally or placebo for eight weeks, with a six-
month follow-up.
No studies were identified that compared oral prostanoid and in-
travenous prostanoid, (oral or intravenous) prostanoid (e.g. ilo-
prost) and cilostazol, aspirin and placebo, cilostazol and placebo,
and aspirin and cilostazol.
Excluded studies
NIne studies were excluded (Bozkurt 2006; Coscia 1972; He
2007; Musial 1986; Reichert 1975; Steinorth 1967; Sun 1993;
Yang 2005; Zelikovsky 1973); the reasons for exclusion are de-
scribed in theCharacteristics of excluded studies table. In brief, the
main reasons for exclusion were interventions with no pharmaco-
logical agents (e.g. acupuncture, sympathectomy; Bozkurt 2006;
He 2007; Yang 2005), studies without patients with Buerger’s dis-
ease (Steinorth 1967), or participants with mixed diagnoses with-
out a separate description of the outcomes for participants with
Buerger’s disease (Coscia 1972; Zelikovsky 1973).
Risk of bias in included studies
See Figure 2 and Figure 3 for a graphical summary of method-
ological quality for the included studies, based on the ’Risk of bias’
domains.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Four included studies (Esato 1995; Fiessinger 1990; Ishitobi 1991;
Verstraete 1998) did not describe the method of randomisation
and therefore, were classed as unclear risk of bias. Only Beigi 2014,
after contact with study authors, was classed as low risk of bias
because the trialists used a computerised randomisation method.
Allocation concealment was only reported in the Fiessinger 1990
study, which reported the utilization of a centre of randomisation.
Beigi 2014, after contactwith study authors, described amethodof
allocation concealment based on computerised codes that were in
the possession of a third person (not involved in drug administra-
tion or outcome assessment). The remaining three studies (Esato
1995; Ishitobi 1991; Verstraete 1998) were classified as unclear
risk of bias.
Blinding
All five included studies were blinded for performance bias. Beigi
2014, Esato 1995 and Fiessinger 1990 were blinded for detection
bias; however, Ishitobi 1991 and Verstraete 1998 did not report
whether the outcome evaluators were blinded.
Incomplete outcome data
Beigi 2014 described a study without losses to follow-up. Follow-
up was available to six months.
Esato 1995 reported they used intention-to-treat analyses, but in
practice, adopted ’as-treated’ (per protocol) analyses. All exclusions
were explained. Follow-up was available to four weeks.
Fiessinger 1990 reported by intention-to-treat, and justified all
the post randomisation exclusions. Follow-up was available to six
months. Fiessinger 1990 was therefore judged to be at low risk of
attrition bias.
In Ishitobi 1991, the authors did not clearly describe the losses to
follow-up, declaring only that there were more losses in the ilo-
prost group, but not reporting how many participants and possi-
ble reasons. Follow-up was available to four weeks. Ishitobi 1991
was judged to be of high risk of attrition bias.
Verstraete 1998 also reported by intention-to-treat, and justified
all the post randomisation exclusions. Follow-up was available to
six months. Therefore, Verstraete 1998 was judged to be at low
risk of attrition bias.
Selective reporting
Esato 1995, Fiessinger 1990, Ishitobi 1991, and Verstraete 1998
described all outcomes and were judged to be at low risk of re-
porting bias. Beigi 2014 did not describe the presence of rest pain
or ischaemic ulcers and was judged to be at high risk of reporting
bias.
Other potential sources of bias
In Esato 1995 and Ishitobi 1991, the study authors did not de-
scribe tobacco exposure before and after the treatment and both
were judged to be at high risk of other bias. Beigi 2014 was judged
to be at high risk of other bias because participants without critical
ischaemia were eligible, resulting in low chances to be amputated.
Verstraete 1998 was judged to be at unclear risk of bias because
there was no information about any potential conflict of interest.
Fiessinger 1990 was judged to be at low risk of bias because the
proportion of smokers and non-smokers in the study arms at the
beginning and after treatment were described.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: Oral prostacyclin analogue (iloprost) versus placebo;
Summary of findings 2 Summary of findings: Intravenous
prostacyclin analogue (iloprost) versus oral aspirin; Summary
of findings 3 Summary of findings: Intravenous prostacyclin
analogue versus intravenous prostaglandin analogue; Summary of
findings 4 Summary of findings: Folic acid versus placebo
(Oral or intravenous) prostanoid versus placebo
Oral prostacyclin analogue (iloprost) versus placebo
One study assessed this comparison (Verstraete 1998).
Primary outcomes
(1) Ulcer healing: assessed at the end of treatment (eight weeks)
and six months after the start of treatment. After eight weeks (end
of treatment), complete healing of all ulcers was 19% in the 200
mcg iloprost group (12/63 participants; RR 1.11; 95% CI 0.54
to 2.29; P = 0.78), 15% in the 400 mcg iloprost group (10/65
participants; RR0.90; 95%CI 0.42 to 1.93; P = 0.78), and 17% in
the placebo group (12/70 participants; Analysis 1.1; Analysis 1.2).
After six months, the 200 mcg iloprost group reported complete
healing of all ulcers in 49% (31/63 participants; RR 1.19; 95%
CI 0.82 to 1.73; P = 0.37), the 400 mcg iloprost group reported
41% (27/65 participants; RR 1.00; 95% CI 0.67 to 1.50; P =
0.99), and the placebo group reported 41% (29/70 participants)
complete healing of all ulcers (Analysis 1.3; Analysis 1.4). None
of these findings were statistically significant.
Verstraete 1998 also reported improvement of the most impor-
tant ulcer (improved healing was not a defined outcome in this
review): improvement of the most important ulcer was 55% in
the 200 mcg iloprost group (P = 0.056 versus placebo), 63% in
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the 400 mcg iloprost group (P = 0.008 versus placebo), and 40%
in the placebo group after eight weeks (end of treatment). After
six months, the 200 mcg iloprost group reported improvement of
the most important ulcer in 84% (P = 0.007 versus placebo), the
400 mcg iloprost group reported improvement in 68% (P = 0.297
versus placebo), and the placebo group reported improvement in
62%. These findings were not statistically significant, except for
400 mcg iloprost at eight weeks of treatment and 200 mcg iloprost
at six months when compared with placebo.
(2) Pain: assessed at the end of treatment (eight weeks) and six
months after the start of treatment. After eight weeks (end of treat-
ment), complete relief of rest pain was 39% in the 200 mcg ilo-
prost group (41/105 participants; RR 1.14; 95% CI 0.79 to 1.63;
P = 0.48), 38% in the 400 mcg iloprost group (41/108 partici-
pants; RR 1.11; 95% CI 0.77 to 1.59; P = 0.58), and 34% in the
placebo group (35/102 participants; Analysis 1.5; Analysis 1.6).
After six months, the 200 mcg iloprost group reported complete
relief of rest pain in 63% (66/105 participants; RR 1.28; 95%
CI 1.00 to 1.64; P = 0.05), the 400 mcg iloprost group reported
49% (53/108 participants; RR 1.00; 95% CI 0.76 to 1.32; P =
0.99), and the placebo group reported 49% (50/102 participants)
complete relief of rest pain (Analysis 1.7; Analysis 1.8). None of
these findings were statistical significant, except for the iloprost
200 mcg group after six months of treatment.
(3) Rate of amputation: Assessed at six months after the start
of treatment, the placebo group reported 9% major amputations
(9/103 participants), the 200 mcg iloprost group reported 4.7%
major amputations (5/106 participants; RR 0.54; 95% CI 0.19
to 1.56; P = 0.25; Analysis 1.9), and the 400 mcg iloprost group
reported 3.6% major amputations (4/110 participants; RR 0.42;
95% CI 0.13 to 1.31; P = 0.13; Analysis 1.10). These findings
were not statistically significant.
Secondary outcomes
Side effects: Participants in the 400 mcg iloprost group developed
about 25% more (68%) side effects than participants in the 200
mcg iloprost group (43%) and the placebo group (38%). Accord-
ing to the study authors, the most frequent side effect reported
was headache (more than 20%), followed by vasodilatation and
trismus (the latter two cases for the high-dose iloprost group only).
Amputation-free survival, walking distance or pain-free walking,
and ankle brachial index were not assessed by Verstraete 1998.
(Oral or intravenous) prostanoid (e.g. iloprost) versus
aspirin
Intravenous prostacyclin analogue (iloprost) versus oral
aspirin
One study assessed this comparison (Fiessinger 1990).
Primary outcomes
(1) Ulcer healing: assessed at the end of treatment (day 28) and
six months after the start of treatment. Complete healing of all
ulcers, assessed by an independent evaluator, in the iloprost group
was 35% (18/52 patients) compared to 13% (6/46 patients) in the
aspirin group at day 28 (RR 2.65; 95% CI 1.15 to 6.11; P = 0.02;
Analysis 2.1); after six months, complete healing of all ulcers in
the iloprost group was 27.45% (14/51 participants) compared to
6.8% (3/44 participants) in the aspirin group (RR 4.03; 95% CI
1.24 to 13.10; P = 0.02; Analysis 2.2).
(2) Pain: assessed at the end of treatment (day 28). Total relief
of rest pain in the iloprost group was 63% (43/68 participants)
compared to 28% (18/65 participants) in the aspirin group (RR
2.28; 95% CI 1.48 to 3.52; P = 0.0002; Analysis 2.3).
(3) Rate of amputation: Six months after the start of treatment,
three participants treated with iloprost and eight treated with as-
pirin required major amputation. This finding was not statistically
significant (RR 0.32; 95% CI 0.09 to 1.15; P = 0.08; Analysis
2.4).
Secondary outcomes
Side effects: Headache, flushing, nausea, and abdominal cramps
were more common in participants treated with iloprost, but ac-
cording to the study authors, no participant in either group had
to be withdrawn because of side-effects.
Amputation-free survival, walking distance or pain-free walking,
and ankle brachial index were not assessed by Fiessinger 1990.
Intravenous prostacyclin analogue versus intravenous
prostaglandin analogue
Two studies assessed this comparison (Esato 1995; Ishitobi 1991).
Esato 1995 compared intravenous prostacyclin analogue clinprost
to intravenous prostaglandin analogue alprostadil. Ishitobi 1991
compared intravenous prostacyclin analogue iloprost to intra-
venous prostaglandin analogue alprostadil.
Primary outcomes
(1) Ulcer healing:Esato 1995 assessed ulcer healing at the end of
treatment (4 weeks). Ulcer healing was evaluated by an assistant
doctor (a medical researcher responsible for recruiting and out-
come evaluation) using metric parameters (ulcer size), presence of
granulation tissue and infection status. Improvement of ischaemic
ulcers were seen in 70.6% (12/17 participants) in the clinprost
group compared to 56.5% (13/23) in the alprostadil group (RR
1.25, 95% of CI 0.78 to 2.00; P = 0.36). Total recuperation was
seen in 23.5% (4/17 patients) in the clinprost group compared to
8.7% (2/23 participants) in the alprostadil group (RR 2.38, 95%
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of CI 0.48 to 11.7). Both outcomes were not statistically signifi-
cant.
Ishitobi 1991 assessed ulcer healing at the end of treatment (day
28). Ulcer healing was assessed by an assistant doctor and was eval-
uated with metric parameters (ulcer size), presence of granulation
tissue, and presence or absence of infection. Posteriorly classified
as ulcer healing improvement in Buerger’s subgroups, the iloprost
group reported 41% (9/22 patients) compared to 41% (11/27)
in the alprostadil group (RR 1.00, 95% CI 0.51 to 1.98). This
finding was not statistically significant.
Ulcer healing data (improvement of ischaemic ulcers) from Esato
1995 and Ishitobi 1991 were pooled and showed no significant
difference between the treatment groups (RR 1.13, 95% CI 0.76
to 1.69; participants = 89; studies = 2; P = 0.54; I² = 0%; Analysis
3.1; Figure 4; Esato 1995; Ishitobi 1991).
Figure 4. Forest plot of comparison: 1 Prostacyclin vs Prostaglandin E1, outcome: 1.1 Ulcer healing.
(2) Pain: Esato 1995 assessed pain at the end of treatment (four
weeks). Pain was evaluated by an assistant doctor. Fifty percent (8/
16 participants) of the clinprost group were free of pain compared
with 13.6% of the alprostadil group (7/22 patients; RR 1.57;
95% CI 0.72 to 3.44; P = 0.26); the results were not statistically
significant (Analysis 3.2).
In Ishitobi 1991, pain was not measured with a validated score or
scale, or a quality of life questionnaire. Pain was assessed using five
levels (1 = much better, 2 = better, 3 = little better, 4 = no differ-
ence, and 5 = worse). Participants in the iloprost group reported
pain as: much better = 21.7% (5/23 patients), better = 34.8% (8/
23 patients), little better = 17.4% (4/23 patients), no difference
= 21.7% (5/23 patients), and worse = 4.4% (1/23 patients). Par-
ticipants in the alprostadil group reported pain as: much better =
28.5% (8/28 patients), better = 32.1% (9/28 patients), little better
= 14.3 % (4/28 patients), no difference = 21.5% (6/28 patients),
and worse = 3.6% (1/28 patients). Ishitobi 1991 reported that this
finding was not statistically significant.
(3)Rate of amputationwas not appraised byEsato 1995 or Ishitobi
1991.
Secondary outcomes
Side effects: Esato 1995 reported that five participants in the clin-
prost group and two participants in the alprostadil group experi-
enced side effects. In the clinprost group, one participant devel-
oped nausea, tinnitus and vertigo in the third week of drug ad-
ministration, without serious repercussion; another three partic-
ipants had modification of blood tests relating to liver function,
but without further repercussions after the drug administration
was ceased, and one participant developed limb edema, probably
not related to the clinprost use. The alprostadil group had one
participant with modification in blood tests relating to liver func-
tion, but also without further repercussions after the drug admin-
istration was ceased, and another participant experienced a heat
sensation in the head, only on the first day of treatment.
Side effects were not clearly specified in Ishitobi 1991 for patients
with Buerger’s disease. Overall, 13 participants (17.3%) in the
iloprost group and11participants (13.9%) in the alprostadil group
experienced side effects, such as headache, vomiting, and flushing.
Amputation-free survival, walking distance or pain-free walking,
and ankle brachial index were not appraised by Esato 1995 or
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Ishitobi 1991.
Any pharmacological agent versus placebo or any
other pharmacological agent
Folic acid versus placebo
One study assessed this comparison (Beigi 2014).
Primary outcomes
(1) Pain assessment: assessed at baseline, two months and six
months, using a Visual Analogue Scale (VAS), a continuous scale,
ranging from 0 to 10, where a higher score means more pain. At
baseline, the mean VAS score in the folic acid group was 7.07
points (SD 2.82), and the placebo group was 5.9 points (SD 2.21),
resulting in MD 1.17; CI -0.66 to 3.00; P = 0.21; at two months,
the folic acid group was 5.45 points (SD 2.75), and the placebo
group was 5.75 points (SD 1.99) resulting in MD -0.30; CI -2.04
to 1.44; P = 0.74. After six months, the folic acid group was 3.46
points (SD 2.57), and the placebo group was 4.82 points (SD
2.46), resulting in MD -1.36; CI -3.17 to 0.45; P = 0.14. None
of these results were statistically significant (Analysis 4.1; Analysis
4.2; Analysis 4.3).
(2) Rate of amputation: assessed at baseline, two months, and six
months after the beginning of treatment. At baseline, five partici-
pants (5/14) in the folic acid group and four participants (4/16) in
the placebo group had minor amputations; one participant (1/14)
in the folic acid group and none of the participants in the placebo
group had a major amputation. There was no change in the num-
ber of participants with amputations during the entire study; that
is, at two months and six months, no new cases of major or minor
amputation were observed. According to the study authors, the
differences between the folic acid and placebo groups were not
statistically significant (Analysis 4.4; Analysis 4.5).
(3) Ulcer healing was not evaluated by Beigi 2014.
Secondary outcomes
Side effects: none reported.
Amputation-free survival, walking distance or pain-free walking,
and ankle brachial index were not assessed by Beigi 2014.
17Pharmacological treatment for Buerger’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intravenous prostacyclin analogue (iloprost) versus oral aspirin for treatment of Buerger’s disease
Patient or population: pat ients with Buerger’s disease
Settings: hospital and community
Intervention: intravenous prostacyclin analogue (iloprost)
Comparison: oral aspirin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
oral aspirin intravenous prostacy-
clin analogue
Ulcer healing
Follow-up: 28 days
Study population RR 2.65 (1.15 to 6.11) 98
(1 RCT)
⊕⊕⊕©1,2
moderate
130 per 1000 346 per 1000
(150 to 797)
Ulcer healing
Follow-up: 6 months
Study population RR 4.03 (1.24 to 13.10) 95
(1 RCT)
⊕⊕⊕©1,2
moderate
68 per 1000 275 per 1000
(86 to 893)
Complete relief of rest
pain
Follow-up: 28 days
Study population RR 2.28 (1.48 to 3.52) 133
(1 RCT)
⊕⊕⊕©1,2
moderate
277 per 1000 631 per 1000
(410 to 975)
Rate of amputation
Follow-up: 6 months
Study population RR 0.32 (0.09 to 1.15) 95
(1 RCT)
⊕⊕⊕©1,2
moderate
182 per 1000 58 per 1000
(16 to 209)
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 one single study (doubt about reproducibility of data), downgraded by one level
2 conf lict of interest not stated but it was not considered suf f icient to downgrade the quality of evidence
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Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger’s disease
Patient or population: pat ients with Buerger’s disease
Settings: hospital and community
Intervention: intravenous prostacyclin analogue (clinprost, iloprost)
Comparison: intravenous prostaglandin analogue (alprostadil)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
intra-
venous prostaglandin
analogue
intravenous prostacy-
clin analogue
Ulcer healing
Follow-up: 28 days
Study population RR 1.13 (0.76 to 1.69) 89
(2 RCTs)
⊕©©©1,2,3,4
very low
480 per 1000 542 per 1000
(365 to 811)
M oderate
486 per 1000 550 per 1000
(370 to 822)
Complete relief of pain
Follow-up: 28 days
Study population RR 1.57 (0.72 to 3.44) 38
(1 RCT)
⊕⊕©©2,3,5
low
318 per 1000 500 per 1000
(229 to 1000)
Rate of amputation
Follow-up: 28 days
see comment - Rate of amputat ion was
not appraised by the
studies in this compari-
son
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 adopt ion of ’as-treated’ (per-protocol) analyses, downgraded by one level
2 absence of pat ients’ smoking history, downgraded by one level
3 conf lict of interest not stated but it was not considered suf f icient to downgrade the quality of evidence
4 small number of part icipants, downgraded by one level
5 one single study (doubt about reproducibility of data), downgraded by one level
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Folic acid versus placebo for treatment of Buerger’s disease
Patient or population: pat ients with Buerger’s disease
Settings: community
Intervention: f olic acid
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Folic acid
Ulcer healing see comment - Ulcer healing was not
appraised by the study
in this comparison
Pain (0 month)
VAS. Scale f rom: 0 to
10; higher score = more
pain
The mean pain in the
placebo group was
5.09 points
The mean pain in the
intervent ion group was
1.17 higher
(0.66 lower to 3.00
higher)
30
(1 RCT)
⊕©©©1
very low
Pain (2 months)
VAS. Scale f rom: 0 to
10; higher score = more
pain
Follow-up: 2 months
The mean pain in the
placebo group was
5.75 points
The mean pain in the
intervent ion group was
0.3 lower
(2.04 lower to 1.44
higher)
30
(1 RCT)
⊕©©©1
very low
Pain (6 months)
VAS. Scale f rom: 0 to
10; higher score = more
pain
Follow-up: 6 months
The mean pain in the
placebo group was
4.82 points
The mean pain in the
intervent ion group was
1.36 lower
(3.17 lower to 0.45
higher)
30
(1 RCT)
⊕©©©1
very low
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Change in rate of am-
putation (2 months)
(Dif ference in number
of amputat ions at start
of treatment)
Follow-up: 2 months
see comment 30
(1 RCT)
⊕©©©1
very low
No new cases of ampu-
tat ions two months af -
ter start of treatment
Change in rate of am-
putation (6 months)
(Dif ference in number
of amputat ions at start
of treatment)
Follow-up: 6 months
see comment 30
(1 RCT)
⊕©©©1
very low
No new cases of ampu-
tat ions six months af ter
start of treatment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; M D: Mean dif ference; VAS: Visual analogue scale
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 part icipants without crit ical ischaemia, result ing in absence of amputat ions and no dif ferences in pain score in both groups,
one single small study - downgraded by three levels
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D I S C U S S I O N
Summary of main results
The five included studies evaluated 602 participants and appraised
the efficacy of prostacyclin or prostaglandin analogues against an-
other drug or placebo, in patients with Buerger’s disease. Folic acid
was also evaluated against placebo in one recent study.
Prostacyclin analogue iloprost, intravenously administered, was
effective in healing ulcers and eradicating rest pain after 28 days
of treatment, when compared with aspirin. However, this evi-
dence was restricted to a single study (133 participants), and con-
sequently, the reproducibility of results is questionable.
Equivalent efficacy was discovered between prostacyclin (iloprost
and clinprost) and prostaglandin (alprostadil) analogues as anal-
ysed by two studies, when evaluating ulcer healing and rest pain
resolution after 28 days of treatment.
Oral prostacyclin analogue iloprost was not effective in healing
ischaemic ulcers or eradicating rest pain whenmeasured at the end
of treatment and six months later, when compared with placebo.
Evidence related to efficacy about rest pain resolution after six
months of treatment with iloprost 200 mcg was inconsistent with
a dose-response relationship, and the magnitude of the effect ob-
served was low (RR 1.28; 95%CI 1.00 to 1.64); thus, the evidence
is questionable.
In patients with Buerger’s disease and hyperhomocysteinaemia,
folic acid, when compared with placebo, did not demonstrate a
protective effect against amputations, because there was an ab-
sence of amputations in both groups. Another outcome presented
was pain; results found no statistically significant differences be-
tween the groups. However, the participants chosen were classed
as Fontaine II; in other words, they did not have rest pain.
In most cases, treatment side effects experienced by the partici-
pants, such as headaches, flushing, or nausea, did not lead to treat-
ment interruptions or more serious consequences.
Overall completeness and applicability of
evidence
The main objective of this review was to assess the effectiveness of
the pharmacological agents administered in patientswithBuerger’s
disease at different stages of ischaemia. However, we identified
only a small number of studies (five randomised controlled trials)
with patients of more severe stages of the disease (ulcers, rest pain,
or both). In fact, more severe cases of Buerger’s disease are often
treated with therapies for limb ischaemia, such as sympathectomy
and pharmacological treatment, rather than limb revascularisa-
tion.
Interventions in the five studies were limited to evaluating
prostaglandin and prostacyclin analogues, and folic acid, and did
not evaluate other pharmacological agents such as cilostazol, clopi-
dogrel, and pentoxifylline versus placebo or each other.
Another important issue concerns the period of treatment. This
was limited to four or eight weeks in the included studies. Perhaps
prolonged administration until, for example, complete healing or
total relief of rest pain, could improve the success of the treatment.
Evidence suggested that iloprost, given intravenously, was more
effective than aspirin in healing ischaemic ulcers and eradicating
rest pain. This evidence was generated with an interesting compar-
ative i.e. aspirin; patients with severe Buerger’s disease with limited
treatment options are often treated as patients with atherosclerotic
aetiology.
Outcomes measured in the studies were limited to assessments of
ulcer healing and pain. Particularly problematic was pain evalua-
tion. No study used a validated pain score or scale, or quality of
life questionnaires, and consequently,more detailed assessments of
pain was not possible. Amputation free-survival, walking distance
or pain-free walking, and ankle brachial index were not assessed
in any of the included studies.
Very-low quality evidence suggested that folic acid did not pro-
vide a protective effect against amputations and rest pain in pa-
tients with Buerger’s disease and hyperhomocysteinaemia. There-
fore, routine folic acid administration in patients with Buerger’s
disease and hyperhomocysteinaemia remains questionable.
Quality of the evidence
Overall, the quality of the evidence was very low tomoderate, with
few studies, a small number of participants and potential for biases
such as randomisation and allocation concealment methods.
We summarized the quality of the evidence for the main com-
parisons (see also Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4):
(1) Oral prostacyclin analogue (iloprost) versus placebo
Classified as moderate and low quality of evidence. The evidence
was obtained from a randomised controlled trial, with overall low
risk of bias. However, just one study was available for this com-
parison and additional data about reproducibility of the outcomes
were not available. In addition, evidence suggesting relief of rest
pain was found with low dose of iloprost (200 mcg) but not with
high dose of iloprost (400 mcg), demonstrating absence of a dose-
response effect and, consequently, downgrading the quality of the
evidence for relief of rest pain after six months to low.
(2) Intravenous prostacyclin analogue iloprost versus oral
aspirin
Classified as moderate quality of evidence. The evidence was ob-
tained from a randomised controlled trial, with low risk of bias,
and showed a large magnitude of effect (RR > 2.0). However, just
one study was available for this comparison and additional data
about reproducibility of the outcomes were not available.
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(3) Intravenous prostacyclin analogue versus intravenous
prostaglandin analogue
Classified as low and very low quality of evidence. The evidence
was obtained from two randomised controlled trials, which were
double-blinded and demonstrated low heterogeneity, but the ev-
idence was downgraded because a small number of participants
was evaluated, and most importantly, the proportion of tobacco
exposure between groups, and before the start of treatment was
not described. In addition, ’as-treated’ (per-protocol) analyseswere
adopted further downgrading the quality of evidence for ulcer
healing.
(4) Folic acid versus placebo
Classified as very-low quality of evidence. One study with a small
number of participants was available for this comparison and ad-
ditional data about reproducibility of the outcomes were not avail-
able. In addition, participants without critical ischaemia were re-
cruited into the trial, resulting in the absence of amputations and
no differences in pain score in both groups.
Potential biases in the review process
The study of Hoshino 1997, which assessed the efficacy of pam-
icogrel (antiplatelet drug) in patients with Buerger’s disease, was
not included in this review because a full report was not available.
Thus, a potential pharmacological agent was not evaluated. An-
other potential bias relates to pain assessment. For the evaluation
of the treatment effect on pain, we only considered absence or
presence of pain in the included studies, because none of the in-
cluded studies used a validated pain scale or score for appropriate
assessment.
Agreements and disagreements with other
studies or reviews
We did not identify any other systematic reviews about the phar-
macological treatment for Buerger’s disease.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was moderate quality evidence that intravenous iloprost
(prostacyclin analogue) was more effective than aspirin for eradi-
cating rest pain and healing ischaemic ulcers in Buerger’s disease,
but oral iloprost was no more effective than placebo.
Low quality evidence suggested there was no difference in ul-
cer healing or pain relief between intravenous prostaglandin ana-
logue alprostadil and prostacyclin (iloprost and clinprost) in severe
Buerger’s disease.
Very-low quality evidence suggested there was no difference in
pain and rates of amputation between folic acid and placebo in
patients with Buerger’s disease and hyperhomocysteinaemia.
In most cases, treatment side effects such as headaches, flushing
or nausea experienced by the participants were not implicated in
treatment interruptions or more serious consequences.
Further high quality trials assessing the effectiveness of pharma-
cological agents (intravenous or oral) in patients with Buerger’s
disease are needed.
Implications for research
We suggest future trials investigating pharmacological treatment of
Buerger’s disease should incorporate the following characteristics.
• Clearly describe the methods of randomisation and
concealment of allocation;
• Include participants with mild/moderate ischaemia, such as
intermittent claudication;
• Evaluate outcomes, such as walking distance, pain-free
walking distance and ankle brachial index;
• Compare prostacyclin versus prostaglandin analogues;
• Investigate pharmacological agents for which there
currently is no RCT evidence such as pentoxifylline, cilostazol
and clopidogrel;
• Assess pain utilizing validated scores/scales;
• Assess quality of life using quality of life scales;
• Evaluate time without amputation (amputation free-
survival);
• Investigate folic acid reposition in patients with Buerger’s
disease, hyperhomocysteinaemia and critical limb ischaemia.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beigi 2014
Methods Study design: RCT parallel group
Participants Country: Iran
Nº patients: 30 (14 in folic acid group and 16 in placebo group)
Setting: community
Mean age: 39; 42 years in folic acid group and 36 years in placebo group
Gender: all male
Inclusion criteria: negative history of hypertension, diabetes mellitus, ischaemic heart
disease, cerebrovascular disease, collagen vascular disease or vasculitis
Exclusion criteria: quote “surgical sympathectomy or any sort of vascular bypass; using
aspirin, calcium channel blocker, B6 or B12; stop smoking during the study and have not
compliance of being treated. Also, patients with hypercoagulative state due to inherited
thrombophilia (factor V Leiden, A202120G prothrombin variant, acquired activated
protein C resistance, protein C and S deficiency, antithrombin deficiency”
Interventions Treatment:
Folic acid group: oral 5 mg folic acid tablet (by Jallinus Pharmacy, Tehran, Iran)
Placebo group: oral placebo with the same colour, size, weight and box (by Amin Phar-
macy, Isfahan, Iran)
Duration of treatment: 1 day - a single dose of folic acid or placebo
Follow-up: 6 months
Outcomes Primary: Major and minor amputations
Notes Conflict of Interest: none declared
The study authors reported the following regarding a link between homocysteine levels
andBuergers disease: quote “At the beginning of the study, homocysteine level was higher
than normal in 19 patients (63%). There was a significant decrease in homocysteine level
during 6 months in folic acid group (P < 0.001), but there was no change in the placebo
group.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation
Allocation concealment (selection bias) Low risk There was a person responsible for allocation con-
cealment; codified using computerised randomisa-
tion, only revealed at the end of the trial
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Beigi 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Doctor responsible for outcome assessment assessed
the patients at the start and at the end of treatment,
but was not responsible for drug administration
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study without losses to follow-up
Selective reporting (reporting bias) High risk Did not describe the development of rest pain or
ischaemic ulcers after the treatment
Other bias High risk Participants without critical ischaemia were eligi-
ble, resulting in low chances to be amputated. Con-
flict of interest: none declared
Esato 1995
Methods Study design: RCT parallel group
Participants Country: Japan
Nº patients: 135, 46 with Buerger’s disease (21 in clinprost group and 25 in alprostadil
group)
Setting: not stated
Mean age: 61.5 years
Gender: not described
Inclusion criteria: patients with Buerger’s disease and ischaemic ulcer < 1 year or rest
pain
Exclusion criteria: patients with previous lower limb revascularization surgery or sympa-
thectomy; contra-indications for prostaglandin use
Interventions Treatment:
Clinprost group: Lipidious emulsion of TTC-909 (clinprost, a prostacyclin analogue): 2
ampoules (1 ampoule with TTC-909 with 1 mL plus 1 ampoule of Lipo PGE1 placebo
with 2 mL) completed with saline solution, resulting in 10 mL of solution applied daily,
a total dose of 2 mcg, intravenously
Alprostadil group: Lipidious emulsion with PGE 1 (alprostadil), 2 ampoules (1 ampoule
with Lipo PGE1 with 2 mL plus 1 ampoule of TTC-909 placebo with 1 mL) completed
with saline solution, resulting in 10 mL of solution applied daily, a total dose of 10 mcg,
intravenously
Duration of treatment: 4 weeks
No follow-up
Outcomes Primary: improvement of rest pain and ischaemic ulcer
Secondary: safety
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Esato 1995 (Continued)
Notes Conflict of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated, but did not describe methods
Allocation concealment (selection bias) Unclear risk Information not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Doctor responsible for outcome assessment assessed
the patients at the start and at the end of treatment,
but was not responsible for drug administration
Incomplete outcome data (attrition bias)
All outcomes
High risk Adoption of “as-treated” (per protocol) analyses
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Absence of patient’s smoking history
Fiessinger 1990
Methods Study design: multicentre RCT
Participants Country: Multicentre in Europe: (9 countries, 26 centres)
Setting: in hospital and community
Nº patients: 152 (19 did not fulfil criteria; 133: 68 in iloprost group and 65 in aspirin
group)
Mean age: not stated
Gender: 116 M; 36 F
Inclusion criteria: patients with Buerger’s disease with rest pain, ischaemic ulcers or
gangrene
Exclusion criteria: patients with diabetes mellitus, other inflammatory vascular diseases,
and amputation or lumbar sympathectomy in the preceding 3 months
Gravity of illness: ulcers or gangrene - 99 patients (65%)
Interventions Treatment:
Iloprost group: Placebo tablet identical to aspirin and a 6-hour infusion of iloprost
(intravenous): in first 3 days, titration to a maximum tolerated dose or 2.0 ng/kg/min.
The maximum dose at day 3 was repeated on days 4 to 28
Aspirin group: 100 mg Aspirin tablet and a 6-hour daily intravenous placebo infusion
Duration of treatment: 28 days
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Fiessinger 1990 (Continued)
Follow-up: 6 months
Outcomes Primary: total relief of rest pain, complete healing of all trophic changes
Secondary: amputation
Notes Conflict of Interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Low risk Randomisation centre was utilized
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed by a physician not involved in the
patient’s management, or with the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post randomisation excluded patients were described
and justified. Performed an ’intention-to-treat’ anal-
yses
Selective reporting (reporting bias) Low risk All outcomes assessed as described in methods. Rele-
vants outcomes described
Other bias Low risk Proportion of smokers to non-smokers in the study
arms at the beginning and after treatment were de-
scribed
Ishitobi 1991
Methods Study design: RCT
Participants Country: Japan
Setting: hospitalised and community
Nº patients: 134 (55 with Buerger’s disease; 25 in iloprost group and 30 in alprostadil
group)
Mean age: not specified.
Gender: the proportion and numbers of participants with Buerger’s disease were not
specified
Inclusion criteria: patients diagnosed with Buerger’s disease
Exclusion criteria: a) patients who had previous surgical treatment for chronic arterial
obstructive disease; b) patients with necrosis, where the judgement of varicose ulcer is
32Pharmacological treatment for Buerger’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ishitobi 1991 (Continued)
unclear; c) patients with haemorraghic events; d) patients with serious liver, kidney, or
heart disease; e) hypersensitivity to medication or drugs; e) pregnancy
Interventions Treatment:
Iloprost group: iloprost 6mcg in a liquid injection. One dose plus 3 doses PGE1 placebo/
day;
Alprostadil group (PGE1): liquid injection containing 20mcg of alprostadil. Three doses
plus 1 dose iloprost placebo/day
Duration of treatment: 28 days
No follow-up
Outcomes Primary: ulcer size, ulcer improvement
Secondary: improvement of rest pain
Notes Conflict of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Does not describe if the outcome assessments were done by the
same person responsible for recruitment
Incomplete outcome data (attrition bias)
All outcomes
High risk More drop-out patients in the iloprost group than in the al-
prostadil group, actual numbers and possible reasons for drop-
out not provided
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Does not described the proportion of smokers to non-smokers
in the groups
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Verstraete 1998
Methods Study design: Multicentre parallel RCT
Participants Country: six countries: Bulgaria, Poland, Portugal, Greece, France, and Israel
Setting: Hospitalised during the first week of treatment; after first week, participants
continued the study as out-patients
Nº patients: 319 (103 in placebo group, 106 in low-dose iloprost group, and 110 in
high-dose iloprost group)
Mean age: 40 years
Gender: 292 M; 27 F
Inclusion criteria: Age under 50 years, current smoker or history of smoking, angio-
graphic criteria compatible with Buerger’s disease with typical arteriographic findings, e.
g. skip lesions below the popliteal artery, corkscrew collaterals, or both (Martorell’s sign)
, or direct collaterals below the knee in the absence of atherosclerotic lesions, and history
of or current superficial thrombophlebitis or vasospastic symptoms
Exclusion criteria : Patients with diabetes mellitus, treated or untreated hypertension
(systolic BP > 160 mmHg/diastolic BP > 95 mmHg), hypercholesterolaemia (> 260 mg/
dL), atrial fibrillation (or other known causes of arterial embolism), and sympathectomy
within the last 3 weeks of entering the study
Interventions Treatment: 3 groups
Iloprost group 1: Day 1: 100 mcg (1 capsule with 50 mcg, twice daily, orally). From day
2 until the end of the study: 200 mcg (2 capsules with 50 mcg, twice daily, orally);
Iloprost group 2: Day 1: 200 mcg (1 capsule with 100 mcg, twice daily, orally). From
day 2 until the end of the study: 400 mcg (2 capsules with 100 mcg, twice daily, orally);
Placebo group: Day 1: One capsule with iloprost placebo, twice daily, orally. From day
2 until the end of the study: two capsules with iloprost placebo, twice daily, orally
Duration of treatment: 8 weeks
Follow-up: 6 months after treatment
Outcomes Primary: total healing of most important trophic lesion
Secondary: total relief of rest pain without analgesics
Combined endpoint: alive without major amputation, no lesion, no rest pain, no anal-
gesics
Notes Conflict of Interest was not described
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
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Verstraete 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Does not describe whether the outcome as-
sessments were done by the same person re-
sponsible for recruitment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses were justified. Performed ’intention-
to-treat’ analyses
Selective reporting (reporting bias) Low risk All outcomes were described
Other bias Unclear risk Conflict of Interest was not described
BP: blood pressure
dL: decilitre
F: female
Kg: kilogram
Lipo PGE1: lipid emulsion of prostaglandin E1
M: male
mcg: microgram
mg: milligram
min: minute
ng: nanogram
PGE1: prostaglandin analogue E1
RCT: randomised controlled trial
TTC-909: prostacyclin analogue clinprost (isocarbacyclin methylester; methyl 5-[(1S,5S,6R,7R)-7-hydroxy-6-[(E)-(S)-3-hydroxy-1-
octenyl] bicyclo[3.3.0]oct-2-en-3-yl] pentanoate)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bozkurt 2006 Compares pharmacological treatment versus lumbar sympathectomy
Coscia 1972 Only one patient with Buerger’s disease showing improvement of claudication after use of nicergoline orally. We
were unable to identify the results for this single patient with Buerger’s disease
He 2007 The study is about a type of acupuncture treatment of Buerger’s disease
Musial 1986 This study assessed the fibrinolytic activity of prostacyclin PGI2 and iloprost during 3 five-hour infusions on
three consecutive days
Reichert 1975 Non-randomised for Buerger’s disease
Steinorth 1967 No patients with Buerger’s disease
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(Continued)
Sun 1993 Compares a drug (prostaglandin) versus acupuncture and oral use of Rotundine/L-Tetrahydropalmatine
Yang 2005 The study is about acupuncture treatment of Buerger’s disease
Zelikovsky 1973 Only two patients with Buerger’s disease with no differences in ischaemic ulcer and rest pain for the combined
group of participants. Results were not presented by disease classification
Characteristics of studies awaiting assessment [ordered by study ID]
Hoshino 1997
Methods Controlled trial (unclear if randomised)
Participants Patients with Buerger’s disease and arteriosclerosis associated with ischaemic ulcer
Interventions Oral parmicogrel with three different doses
Outcomes Ulcer healing
Notes full text not available
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D A T A A N D A N A L Y S E S
Comparison 1. Oral prostacyclin analogue (iloprost) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ulcer healing (8 weeks) - iloprost
200 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Ulcer healing (8 weeks) - iloprost
400 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Ulcer healing (6 months) -
iloprost 200 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Ulcer healing (6 months) -
iloprost 400 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Complete relief of rest pain (8
weeks) - iloprost 200 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Complete relief of rest pain (8
weeks) - iloprost 400 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Complete relief of rest pain (6
months) - iloprost 200 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Complete relief of rest pain (6
months) - iloprost 400 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Rate of amputation - iloprost
200 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Rate of amputation - iloprost
400 mcg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ulcer healing (4 weeks) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Ulcer healing (6 months) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Complete relief of rest pain (4
weeks)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Rate of amputation 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 3. Prostacyclin versus prostaglandin E1
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ulcer healing 2 89 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.76, 1.69]
2 Complete relief of pain 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Folic acid versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain (0 month) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Pain (2 months) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Pain (6 months) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Change in rate of amputation (2
months)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Change in rate of amputation (6
months)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 1 Ulcer healing
(8 weeks) - iloprost 200 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 1 Ulcer healing (8 weeks) - iloprost 200 mcg
Study or subgroup iloprost 200 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 12/63 12/70 1.11 [ 0.54, 2.29 ]
0.01 0.1 1 10 100
placebo iloprost
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Analysis 1.2. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 2 Ulcer healing
(8 weeks) - iloprost 400 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 2 Ulcer healing (8 weeks) - iloprost 400 mcg
Study or subgroup iloprost 400 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 10/65 12/70 0.90 [ 0.42, 1.93 ]
0.01 0.1 1 10 100
placebo iloprost
Analysis 1.3. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 3 Ulcer healing
(6 months) - iloprost 200 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 3 Ulcer healing (6 months) - iloprost 200 mcg
Study or subgroup iloprost 200 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 31/63 29/70 1.19 [ 0.82, 1.73 ]
0.01 0.1 1 10 100
placebo iloprost
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Analysis 1.4. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 4 Ulcer healing
(6 months) - iloprost 400 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 4 Ulcer healing (6 months) - iloprost 400 mcg
Study or subgroup iloprost 400mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 27/65 29/70 1.00 [ 0.67, 1.50 ]
0.01 0.1 1 10 100
placebo iloprost
Analysis 1.5. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 5 Complete
relief of rest pain (8 weeks) - iloprost 200 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 5 Complete relief of rest pain (8 weeks) - iloprost 200 mcg
Study or subgroup iloprost 200 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 41/105 35/102 1.14 [ 0.79, 1.63 ]
0.01 0.1 1 10 100
placebo iloprost
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Analysis 1.6. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 6 Complete
relief of rest pain (8 weeks) - iloprost 400 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 6 Complete relief of rest pain (8 weeks) - iloprost 400 mcg
Study or subgroup iloprost 400 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 41/108 35/102 1.11 [ 0.77, 1.59 ]
0.01 0.1 1 10 100
placebo iloprost
Analysis 1.7. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 7 Complete
relief of rest pain (6 months) - iloprost 200 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 7 Complete relief of rest pain (6 months) - iloprost 200 mcg
Study or subgroup iloprost 200 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 66/105 50/102 1.28 [ 1.00, 1.64 ]
0.01 0.1 1 10 100
placebo iloprost
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Analysis 1.8. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 8 Complete
relief of rest pain (6 months) - iloprost 400 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 8 Complete relief of rest pain (6 months) - iloprost 400 mcg
Study or subgroup iloprost 400 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 53/108 50/102 1.00 [ 0.76, 1.32 ]
0.01 0.1 1 10 100
placebo iloprost
Analysis 1.9. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 9 Rate of
amputation - iloprost 200 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 9 Rate of amputation - iloprost 200 mcg
Study or subgroup iloprost 200 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 5/106 9/103 0.54 [ 0.19, 1.56 ]
0.01 0.1 1 10 100
iloprost placebo
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Analysis 1.10. Comparison 1 Oral prostacyclin analogue (iloprost) versus placebo, Outcome 10 Rate of
amputation - iloprost 400 mcg.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 1 Oral prostacyclin analogue (iloprost) versus placebo
Outcome: 10 Rate of amputation - iloprost 400 mcg
Study or subgroup iloprost 400 mcg placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verstraete 1998 4/110 9/103 0.42 [ 0.13, 1.31 ]
0.01 0.1 1 10 100
iloprost placebo
Analysis 2.1. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 1
Ulcer healing (4 weeks).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Outcome: 1 Ulcer healing (4 weeks)
Study or subgroup iloprost aspirin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fiessinger 1990 18/52 6/46 2.65 [ 1.15, 6.11 ]
0.01 0.1 1 10 100
aspirin iloprost
43Pharmacological treatment for Buerger’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 2
Ulcer healing (6 months).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Outcome: 2 Ulcer healing (6 months)
Study or subgroup iloprost aspirin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fiessinger 1990 14/51 3/44 4.03 [ 1.24, 13.10 ]
0.01 0.1 1 10 100
aspirin iloprost
Analysis 2.3. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 3
Complete relief of rest pain (4 weeks).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Outcome: 3 Complete relief of rest pain (4 weeks)
Study or subgroup iloprost aspirin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fiessinger 1990 43/68 18/65 2.28 [ 1.48, 3.52 ]
0.01 0.1 1 10 100
aspirin iloprost
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Analysis 2.4. Comparison 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 4
Rate of amputation.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 2 Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Outcome: 4 Rate of amputation
Study or subgroup iloprost aspirin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fiessinger 1990 3/51 8/44 0.32 [ 0.09, 1.15 ]
0.01 0.1 1 10 100
iloprost aspirin
Analysis 3.1. Comparison 3 Prostacyclin versus prostaglandin E1, Outcome 1 Ulcer healing.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 3 Prostacyclin versus prostaglandin E1
Outcome: 1 Ulcer healing
Study or subgroup Prostacyclin Prostaglandin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Esato 1995 12/17 13/23 52.8 % 1.25 [ 0.78, 2.00 ]
Ishitobi 1991 9/22 11/27 47.2 % 1.00 [ 0.51, 1.98 ]
Total (95% CI) 39 50 100.0 % 1.13 [ 0.76, 1.69 ]
Total events: 21 (Prostacyclin), 24 (Prostaglandin)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Prostaglandin E1 Prostacyclin
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Analysis 3.2. Comparison 3 Prostacyclin versus prostaglandin E1, Outcome 2 Complete relief of pain.
Review: Pharmacological treatment for Buerger’s disease
Comparison: 3 Prostacyclin versus prostaglandin E1
Outcome: 2 Complete relief of pain
Study or subgroup Prostacyclin Prostaglandin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Esato 1995 8/16 7/22 1.57 [ 0.72, 3.44 ]
0.01 0.1 1 10 100
Prostaglandin E1 Prostacyclin
Analysis 4.1. Comparison 4 Folic acid versus placebo, Outcome 1 Pain (0 month).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 4 Folic acid versus placebo
Outcome: 1 Pain (0 month)
Study or subgroup Folic acid placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Beigi 2014 14 7.07 (2.82) 16 5.9 (2.21) 1.17 [ -0.66, 3.00 ]
-10 -5 0 5 10
Folic acid placebo
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Analysis 4.2. Comparison 4 Folic acid versus placebo, Outcome 2 Pain (2 months).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 4 Folic acid versus placebo
Outcome: 2 Pain (2 months)
Study or subgroup Folic acid placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Beigi 2014 14 5.45 (2.75) 16 5.75 (1.99) -0.30 [ -2.04, 1.44 ]
-10 -5 0 5 10
Folic acid placebo
Analysis 4.3. Comparison 4 Folic acid versus placebo, Outcome 3 Pain (6 months).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 4 Folic acid versus placebo
Outcome: 3 Pain (6 months)
Study or subgroup Folic acid placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Beigi 2014 14 3.46 (2.57) 16 4.82 (2.46) -1.36 [ -3.17, 0.45 ]
-10 -5 0 5 10
Folic acid placebo
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Analysis 4.4. Comparison 4 Folic acid versus placebo, Outcome 4 Change in rate of amputation (2 months).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 4 Folic acid versus placebo
Outcome: 4 Change in rate of amputation (2 months)
Study or subgroup Folic acid placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beigi 2014 0/14 0/16 Not estimable
0.01 0.1 1 10 100
Folic acid placebo
Analysis 4.5. Comparison 4 Folic acid versus placebo, Outcome 5 Change in rate of amputation (6 months).
Review: Pharmacological treatment for Buerger’s disease
Comparison: 4 Folic acid versus placebo
Outcome: 5 Change in rate of amputation (6 months)
Study or subgroup Folic acid placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beigi 2014 0/14 0/16 Not estimable
0.01 0.1 1 10 100
Folic acid placebo
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A P P E N D I C E S
Appendix 1. CRS search strategy
#1 Buerger:TI,AB,KY 22
#2 Buerger*:TI,AB,KY 22
#3 MESH DESCRIPTOR Thromboangiitis Obliterans 12
#4 (thromboang* near/2 oblit*):TI,AB,KY 0
#5 (thromboang* near oblit*):TI,AB,KY 30
#6 (endangitis obliterans):TI,AB,KY 0
#7 Winiwarter:TI,AB,KY 0
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 37
Appendix 2. LILACS search strategy
(MH:“Thromboangiitis Obliterans” OR “Tromboangeítis Obliterante” OR “ Tromboangeíte Obliterante” OR “Doença de Buerger”
OR “C14.907.137.870” OR “C14.907.940.905”) AND (DB: (“IBECS” OR “LILACS”)) : 38 results
Appendix 3. ISRCTN search strategy
buerger 6
buerger* 6
thromboang* 0
(thromboang* oblit*) 0
“endagitis obliterans” 0
winiwarter 0
buerger ORbuerger* OR thromboang* OR (thromboang* oblit*)
OR “endagitis obliterans” OR winiwarter
6
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Appendix 4. Clinicaltrials.gov search strategy
buerger 8
buerger* 0
thromboang* 0
(thromboang* oblit*) 0
“endagitis obliterans” 0
winiwarter 0
buerger ORbuerger* OR thromboang* OR (thromboang* oblit*)
OR “endagitis obliterans” OR winiwarter
8
Appendix 5. The Australian New Zealand Clinical Trials Registry search strategy
buerger 0
buerger* 0
thromboang* 0
(thromboang* oblit*) 0
“endagitis obliterans” 0
winiwarter 0
buerger ORbuerger* OR thromboang* OR (thromboang* oblit*)
OR “endagitis obliterans” OR winiwarter
0
Appendix 6. The EU clinical Trials Register search strategy
buerger 2
buerger* 2
thromboang* 0
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(Continued)
(thromboang* oblit*) 0
“endagitis obliterans” 0
winiwarter 1
buerger ORbuerger* OR thromboang* OR (thromboang* oblit*)
OR “endagitis obliterans” OR winiwarter
21
Appendix 7. The World Health Organization International Clinical Trials Registry Platform search
strategy
buerger 20
buerger* 22
thromboang* 6
(thromboang* oblit*) 6
“endagitis obliterans” 0
winiwarter 0
buerger ORbuerger* OR thromboang* OR (thromboang* oblit*)
OR “endagitis obliterans” OR winiwarter
24
Appendix 8. OpenGrey Database search strategy
buerger’s disease 3
thromboangiitis obliterans 2
von Winiwarter disease 0
buerger’s disease OR thromboangiitis obliterans OR von Wini-
warter disease
3
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F E E D B A C K
Quality of evidence, 2 February 2016
Summary
Comment: You say that: “Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR)
2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest
pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence)”.
For ulcer healing the data are from Analysis 2.1, from a single study done 25 years ago. It showed 18/52 with iloprost and 6/46 with
aspirin. The definition of moderate evidence is that “further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate”. Quite right, and here I repeated the analysis with a single misclassification error
simulated, so that the numbers were 17/52 vs 7/46. The relative risk then became 2.15 (0.98 to 4.72). In other words, not significant,
with results from a single patient changed.
Fiessinger 1990 has no data on 4-week ulcer healing, and so far as I can see there is no explanation from whence these numbers are
derived. No is any reason given as to why the denominators in the calculations are different from both the numbers randomised (68
and 65) or those followed in the longer term (51 and 44).
Some points.
1: Fiessinger 1990 gives a beautiful explanation of a double-blind double dummy method, and while it is low risk, a simple statement
of double blind is insufficient given that one treatment is an infustion and the other a tablet.
2: There is no explanation of where the numbers come from.
3: And given the very considerable literature concerning the dangers of doing sums on small numbers of patients and events, surely the
true answer for ulcer healing here is that we just don’t know. If one patient can make a difference between significant to not significant,
the surely the quality of the evidence is very low. And that is at best. Almost all statistical results here derive from small numbers of
participants and events from single studies. The reality is that we can’t know given the paucity of data available.
Personally, I think that the GRADE system, with three categories where one might expect results to be altered, is the real problem.
Moderate quality sounds good, but the definition of moderate that ”further research is likely to have an important impact on our
confidence in the estimate of effect and may change the estimate“ is no different from low. very low quality is the preserve of very small
numbers, as here.
Reply
The Cochrane Vascular editorial base has asked the review authors to respond to the feedback.
Contributors
Feedback: Prof Andrew Moore, University of Oxford, Cochrane author and editor
I do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment
Response: Marlene Stewart, Managing Editor, Cochrane Vascular
WH A T ’ S N E W
Last assessed as up-to-date: 13 April 2015.
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Date Event Description
9 February 2016 Feedback has been incorporated Feedback received. Authors invited to respond to feed-
back
3 February 2016 Amended Author order amended on request of authors
3 February 2016 New citation required but conclusions have not changed Author order amended on request of authors
C O N T R I B U T I O N S O F A U T H O R S
DGC is the contact person with the editorial base.
DGC drafted the clinical section of the background and will respond to the clinical comments of the referees.
DGC responded to the methodology and statistics comments of the referees.
DGC and JCCBS contributed to writing the protocol.
DGC wrote the final draft of the protocol and review.
DGC, JCCBS, CRM selected studies, extracted data, performed data analysis and wrote the review.
DGC is the guarantor of the final review.
CRM: methodological supervision.
D E C L A R A T I O N S O F I N T E R E S T
DGC: none known
CRM: none known
JCCBS: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Office.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
New review author (Cristiane R Macedo) joined the review team.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Alprostadil [therapeutic use]; Amputation [statistics & numerical data]; Aspirin [therapeutic use]; Epoprostenol [analogs & derivatives;
therapeutic use]; Iloprost [therapeutic use]; Prostaglandins [therapeutic use]; Randomized Controlled Trials as Topic; Thromboangiitis
Obliterans [∗drug therapy; surgery]; Ulcer [drug therapy]
MeSH check words
Adult; Humans; Male; Middle Aged
54Pharmacological treatment for Buerger’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
